The long development saga of U.S. Bioscience Inc.'s Ethyol chemoprotectant has finally come to a successful close, with the FDA granting the drug unconditional approval last week. The company also solidified its cash position, more than tripling the $15.3 million it had at Sept. 30 through a $29 million private placement (see page B12) and $20 million to come from a new partnership with Alza Corp.

Now the proof will be in the marketing.